Amicus Therapeutics ( FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration. This stock is trading up 9.6% to $5.67 in recent trading. Today's Range: $5.45-$6.15 52-Week Range: $2.10-$7.29 Volume: 1.3 million Three-Month Average Volume: 241,632 >>5 Stocks Poised for Breakouts From a technical perspective, FOLD is gapping up sharply here back above its 50-day and 200-day moving averages with heavy volume. This move has briefly pushed FOLD into breakout territory, since the stock has flirted with some near-term overhead resistance at $5.74. At last check, FOLD has hit an intraday high of $6.15 but it has subsequently pulled back to around $5.60. Traders should now look for long-biased trades in FOLD as long as its trending above $5.74 to today's high of $6.15 with strong upside volume flows. I would consider any upside volume day that registers near or above 241,632 shares as bullish. If FOLD can maintain that trend, then look for this stock to re-test or possibly take out its next significant overhead resistance levels at $6.89 to $7.29, and possibly $8 to $8.12 in the near future. Amicus was included in a list of 22 Biopharma Stocks With Breakout Potential in 2012.